Thomas Porter, MD
Cardiovascular Disease · Omaha, NENPI 1831140391
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $7,200 of the $10,974 with a category attached, or 65.6%. Lantheus Medical Imaging, Inc. accounts for 60.4% of it on its own, with 3 other manufacturers making up the rest. Reporting peaked in 2019 at $4,633 and has fallen 99.6% since, to $18 in 2024.
Across 16 payments — averaging $685.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lantheus Medical Imaging, Inc.$7K
- GE HealthCare$4K
- Progenics Pharmaceuticals, Inc.$107
- Abiomed$34
Across 2 payments — averaging $26,323 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Lantheus Medical Imaging, Inc.$53K
What the payments were for
- Consulting fees$2,00018%
- Speaking & faculty fees$7,20066%
- Travel & lodging$1,60015%
- Food & beverage$1742%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lantheus Medical Imaging, Inc. | 10 | $6,633 |
| GE HealthCare | 3 | $4,200 |
| Progenics Pharmaceuticals, Inc. | 1 | $107 |
| Abiomed | 2 | $34 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$10,974 in reported general payments places this provider in the 85th percentile of 97 cardiovascular disease providers in Nebraska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 244 | $303,431 |
| JardianceEmpagliflozin | 167 | $181,976 |
| EntrestoSacubitril/Valsartan | 99 | $137,607 |
| Repatha SureclickEvolocumab | 138 | $72,021 |
| XareltoRivaroxaban | 64 | $69,384 |
| Praluent PenAlirocumab | 115 | $65,719 |
| FarxigaDapagliflozin Propanediol | 22 | $37,776 |
| OzempicSemaglutide | 23 | $24,407 |
| VascepaIcosapent Ethyl | 21 | $19,202 |
| Pyridostigmine Bromide | 34 | $7,225 |
| Ezetimibe | 326 | $6,828 |
| NexletolBempedoic Acid | 12 | $6,389 |
| Metoprolol Succinate | 389 | $5,389 |
| Rosuvastatin Calcium | 428 | $4,547 |
| Atorvastatin Calcium | 461 | $3,639 |
Paid to pharmacies, not to this prescriber.
Other cardiovascular disease in Omaha
- Ronald ZoltyOmaha$945K
- Jeffrey CarstensOmaha$124K
- John HenryOmaha$79K
- Joseph ThibodeauOmaha$75K
- Qais RadaidehOmaha$50K
- Edward OlearyOmaha$36K
- Faris KhanOmaha$17K
- Michael PetersOmaha$13K
- Gregory PavlidesOmaha$10K
- Shiva PonamgiOmaha$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.